ADVISORY/ZymoGenetics to Highlight Development Programs at Needham & Company Biotechnology Conference; Webcast of presentation on Thursday, June 5, 2003.Business Editors/Health/Medical Writers ADVISORY...for Thursday (June 5) SEATTLE--(BUSINESS WIRE)--June 2, 2003 ZymoGenetics, Inc. (Nasdaq:ZGEN) announced today that James Johnson James Johnson may refer to: Artists, authors, and musicians
New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Mr. Johnson will provide an overview of the company and review corporate goals and development activities. Mr. Johnson's presentation will be at 4:30 pm (Eastern Time) on Thursday, June 5, 2003. A live audio webcast of the presentation can be accessed by going to the investor relations Investor relations The process by which the corporation communicates with its investors. section of the Company's website at www.zymogenetics.com. It is recommended that listeners log into the webcast prior to the start in order to download any software that may be required. The webcast will be archived on the company website for 14 days after the presentation. About ZymoGenetics ZymoGenetics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic proteins for the prevention or treatment of human diseases. Using a product discovery engine, comprising genomics, bioinformatics, protein chemistry and preclinical biology, ZymoGenetics has generated a broad pipeline of proprietary product candidates. ZymoGenetics intends to commercialize these product candidates through internal development, collaborations with biopharmaceutical partners, and out-licensing of its extensive patent portfolio. For further information, visit www.zymogenetics.com. This press release contains "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These forward-looking statements are based on the current intent and expectations of the management of ZymoGenetics. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. ZymoGenetics' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with our unproven discovery strategy, preclinical and clinical development, regulatory oversight, intellectual property claims and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risks detailed in the company's public filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2002. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion